Stem Cell Sciences Signs Service Agreement With...

CAMBRIDGE, England, November 20 /PRNewswire/ --     Stem Cell Sciences plc 
(AIM:STEM, ASX:STC), a company focused on the
commercialisation of stem cells and stem cell technologies, has signed a
Master Service Agreement of up to five years with Pfizer Limited, the UK
operating unit of the global research-based pharmaceutical company Pfizer,
Inc. (NYSE: PFE). Under the terms of the agreement, SCS will provide research
services, cell lines, media and reagents to support Pfizer's R&D efforts in
this important field.



    Dr Alastair Riddell, CEO of SCS, said, "The opening of Pfizer's
new regenerative medicine research facility in Cambridge, UK, last week is
very important for stem cell research and reinforces the UK's position as an
international centre of excellence. We are therefore very pleased to be able
to support Pfizer's efforts to advance biomedical research under our new
agreement."



    The Pfizer regenerative medicine unit will be led by Chief
Scientific Officer, Ruth McKernan, PhD, who said, "I'm very excited to lead
this new research unit. While there is still a lot to understand about how
stem cells can be used therapeutically, we believe it is one of the most
promising areas of scientific research. Building successful partnerships with
companies such as Stem Cell Sciences will be important for us."



About Stem Cell Sciences plc

    Stem Cell Sciences (SCS) is an international research and
development company focusing on the commercial application of stem cell
biology technologies for drug discovery and regenerative medicine research.
Stem Cell Sciences is now focussing on building revenues through the sale of
products, collaborative research and licensing deals with international
biotechnology and pharmaceutical companies.



    Stem Cell Sciences has a substantial portfolio of patents and
patent applications in both adult and embryonic stem cell fields. The Company
has been active in the stem cell research field since 1994, principally
focused on technologies to grow, differentiate, and purify adult and
embryonic stem cells. These include technologies to permit the generation of
highly purified stem cells and their differentiated progeny (specialised
tissue cell types) for use in genetic, pharmacological and toxicological
screens. Moreover, these technologies may be able to provide pure populations
of appropriate cell types for transplantation therapies in the future.



    The Company has its main research base and headquarters in
Cambridge, UK with a second research base in Monash near Melbourne, Australia
and a business development office in San Francisco, USA.



    For further information on the company please visit:
http://www.stemcellsciences.com.



    
    For further information, please contact:

    Stem Cell Sciences plc (United Kingdom),
    Alastair Riddell, CEO,
    Tim Allsopp, Chief Scientific Officer,
    [phone];

    Stem Cell Sciences pty ltd (Australia),
    Paul Bello, Operations Manager,
    [phone];

    Citigate Dewe Rogerson (For SCS, UK),
    Mark Swallow / Emma Palmer Foster / Amber Bielecka,
    [phone];

    Talk Biotech (For SCS, Australia),
    Fay Weston, Director,
    [phone];

    Daniel Stewart & Company (NOMAD to SCS, UK),
    Simon Leathers / Simon Starr,
    [phone]